Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2016-07-06 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2016-07-06 English
Regulatory Filings 2016
Regulatory Filings Classification · 90% confidence The document text appears to be encoded or corrupted and does not contain any readable content, keywords, regulatory headers, fiscal period dates, or document titles that would allow classification into any specific filing category. The length is 7789 characters, which is sufficient for a report, but the content is not interpretable. Given the lack of meaningful content and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2016-06-09 English
Regulatory Filings 2016
Regulatory Filings Classification · 90% confidence The document text appears to be heavily encoded or corrupted, containing no clear readable content, titles, or keywords that indicate a specific type of financial or corporate filing. There are no references to fiscal periods, regulatory bodies, report titles, or any substantive financial data. The length is 7271 characters, which is sufficient for a report, but the content is not interpretable as a report or announcement. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2016-06-07 English
Regulatory Filings 2016
Regulatory Filings
2016-06-07 English
PRIMARY DOCUMENT
Director's Dealing
2016-06-03 English
4
Director's Dealing
2016-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.